Evidence map›Paper›PMID 32111220›Full record

ArticleBMC musculoskeletal disorders2020

Injections of concentrated bone marrow aspirate as treatment for Discogenic pain: a retrospective analysis.

Michael Wolff, Jon Mark Shillington, Christopher Rathbone, Shawn K Piasecki, Brian Barnes

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints-A Systematic Review of the Literature.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025
    Pooled it
  2. Stem cells and discogenic back pain.British medical bulletin · 2023
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Recent Advances in Managing Spinal Intervertebral Discs Degeneration.International journal of molecular sciences · 2022
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Michael WolffSouthwest Spine and Sports, 9913 N. 95th St, Scottsdale, AZ, 85258, USA. mww@swssaz.com.ORCID http://orcid.org/0000-0003-4760-9174
Jon Mark ShillingtonSouthwest Spine and Sports, 9913 N. 95th St, Scottsdale, AZ, 85258, USA.
Christopher RathboneUniversity of Texas at San Antonio, San Antonio, TX, USA.
Shawn K PiaseckiIsto Biologics, Hopkinton, MA, USA.
Brian BarnesIsto Biologics, Hopkinton, MA, USA.
Centre National de la Recherche Scientifique · FRMinistry of Youth and Sports · ROThe University of Texas at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are an overwhelming number of patients suffering from low back pain (LBP) resulting from disc pathology. Although several strategies are being developed pre-clinically, simple strategies to treat the large number of patients currently affected is still needed. One option is to use concentrated bone marrow aspirate (cBMA), which may be effective due to its intrinsic stem cells and growth factors.

methodsThirty-three patients who received intradiscal injections of cBMA to relieve LBP were followed up based on Numeric Rating Scale (NRS), Oswestry Low Back Pain Disability Index (ODI), and Short Form-36 Health Survey (SF-36) scores. Patients were also subdivided into those with a pre-injection NRS > 5 and pre-injection NRS ≤ 5. The proportion of patients demonstrating at least 50% improvement (and 95% confidence intervals) from baseline at five follow-up visits for each outcome was evaluated.

resultsAt least 50% improvement in NRS was observed for 13.8, 45.8, 41.1, 23.5, and 38.9% of patients across five follow-up visits, out to 1 year. When stratified by high (> 5) versus low (≤ 5) baseline NRS scores, the values were 14.3, 45.5, 71.4, 22.2, and 44.4% among those with high baseline pain, and 13.3, 46.2, 20.0, 25.0, and 33.3% among those with low baseline pain. The 50% improvement rates across visits were 4.3, 28.6, 30.0, 22.2, and 30.8% for SF-36, and 4.2, 26.7, 36.4, 55.6, and 30.8% for ODI.

conclusionsIntradiscal cBMA injections may be effective to reduce pain and improve function. Patients with relatively higher initial pain may have potential for greatest improvement.

Indexed as

Point-of-Care SystemsAdultAgedBone Marrow TransplantationDisability EvaluationFemaleFollow-Up StudiesHumansInjections, IntralesionalIntervertebral DiscIntervertebral Disc DegenerationLow Back PainLumbar VertebraeMaleMiddle AgedPain MeasurementBone marrow aspirateDiscogenicIntradiscalLow back painMesenchymal stem cellPlatelet-rich plasma

Identifiers

PMID32111220
PMCPMC7049206
OpenAlexW3010650703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.